# Christy L. Shaffer

> Christy L. Shaffer is a Series A investor at Artizan Biosciences backing Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Artizan Biosciences](https://shizune.co/investors/profile/artizan-biosciences)
- Location: Raleigh, United States
- Total investments: 5
- Last investment: Apr 2026
- Lead investor: 40%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/christy-l-shaffer-5649395/

Christy L. Shaffer is a General Partner at Hatteras Venture Partners and was a President and CEO at Inspire Pharmaceuticals. She attended The University of Tennessee Health Science Center.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 60% |
| Therapeutics | 3 | 60% |
| Biotechnology | 2 | 40% |
| Medical | 1 | 20% |
| Analytics | 1 | 20% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 60% |
| Angel | 1 | 20% |
| Series B | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Incyclix Bio | Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers. Founded by Patrick Roberts, Jay Strum, John Bisi, and Fred Eshelman in 2020 and is headquartered in Durham, North Carolina. | $5M | Series B | Apr 08, 2026 |  |
| Aer Therapeutics | Aer Therapeutics is a clinical-stage biopharmaceutical company that develops an approach to treat lung disease with excess mucus and mucus plugs. The company focuses on treating respiratory diseases with significant unmet needs, such as COPD, cystic fibrosis, and asthma. | $36M | Series A | Apr 13, 2023 |  |
| Trefoil Therapeutics | Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and causea significant amount of preventable blindness throughout the world.Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering.The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition. | $28M | Series A | Dec 01, 2021 |  |
| EvoApp | EvoApp makes analyzing big data easy by finding the patterns in relevant conversations that impact business decisions.Their real-time data mining and analysis platform gives big data meaning by correlating with metrics that drive businesses. They’ve helped customers quadruple lead generation, dramatically improve customer service, find thelanguage that makes them six times more relevant to their target audience and accelerate product launches.Connecting big data with business metrics provides new and better ways to answer the questions critical to success. EvoApp makes big data actionable with a scalable analysis platform previously only available to the largest institutions. They make big data approachable with solutions for every day users. EvoApp was founded by two NCSSM alumni, Joe Davy and Alexey Melnichenko in May 2009. |  | Series A | Jan 31, 2011 |  |
| EvoApp | EvoApp makes analyzing big data easy by finding the patterns in relevant conversations that impact business decisions.Their real-time data mining and analysis platform gives big data meaning by correlating with metrics that drive businesses. They’ve helped customers quadruple lead generation, dramatically improve customer service, find thelanguage that makes them six times more relevant to their target audience and accelerate product launches.Connecting big data with business metrics provides new and better ways to answer the questions critical to success. EvoApp makes big data actionable with a scalable analysis platform previously only available to the largest institutions. They make big data approachable with solutions for every day users. EvoApp was founded by two NCSSM alumni, Joe Davy and Alexey Melnichenko in May 2009. |  | Angel | Oct 15, 2010 |  |

5 of 5 investments shown.

## Co-investors
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 1 deal together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 1 deal together

## About Artizan Biosciences

VC Fund · New York, United States

Artizan Biosciences provides pharmaceutical drug development services, namely, the development of small molecule drugs for use in humans. The Durham-based biotech company declined to disclose its intended use of the proceeds from this offering, as well as its current revenue range.

5 contacts available at Artizan Biosciences.

| Name | Title | Profile |
| --- | --- | --- |
| Christy L. Shaffer | Chair Of The Board Of Directors | https://shizune.co/investors/profile/christy-l-shaffer |
| Christy L. Shaffer | Chair Of The Board Of Directors | https://shizune.co/investors/profile/christy-shaffer |
| James Rosen | CEO | https://shizune.co/investors/profile/james-rosen |
| Marcel de Zoete | Founder & Consultant | https://shizune.co/investors/profile/marcel-de-zoete |
| Noah Palm | Founder | https://shizune.co/investors/profile/noah-palm |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Christy L. Shaffer invest in?

Christy L. Shaffer invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A and Angel stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Christy L. Shaffer last invest?

The most recent investment recorded for Christy L. Shaffer closed in Apr 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co